MarketPulse

gene editing

5 articles
The Motley FoolThe Motley Fool··David Jagielski, Cpa

CRISPR Therapeutics Stock Slumps 9% Despite Casgevy Approval and Strong Cash Position

CRISPR Therapeutics stock declined 9% following a $585.2M convertible notes offering. The gene-editing company boasts FDA-approved Casgevy therapy and $1.8B in reserves but faces steep losses.
VRTXCRSPgene editingCasgevy
GlobeNewswire Inc.GlobeNewswire Inc.··Na

Editas Medicine Slashes Q4 Losses While Advancing CRISPR Therapy Toward Human Trials

Editas Medicine reported Q4 2025 net loss of $5.6M, down 88% YoY. Lead CRISPR therapy EDIT-401 shows >90% LDL-C reduction; IND submission expected mid-2026.
BMYCELGrEDITclinical trialCRISPR
The Motley FoolThe Motley Fool··Prosper Junior Bakiny

Vertex Over CRISPR: Why Profitable Gene-Editing Beats Pipeline Dreams

Vertex Pharmaceuticals offers profitable gene-editing exposure versus CRISPR's pipeline-dependent model. Casgevy's slow adoption and high costs make Vertex's diversified, profitable business more attractive for risk-averse investors despite lower upside potential.
VRTXCRSPclinical trialspipeline candidates
GlobeNewswire Inc.GlobeNewswire Inc.··Prime Medicine, Inc.

Prime Medicine to Present at Three Major Biotech Conferences in March

Prime Medicine will present at three major biotech conferences in March 2026, including TD Cowen and Citizens Life Sciences, with webcasts available afterward.
PRMEclinical developmentinvestor conference
The Motley FoolThe Motley Fool··Adria Cimino

Vertex Pharmaceuticals Diversifies Beyond Cystic Fibrosis With Gene-Editing Expansion

Vertex Pharmaceuticals expands beyond cystic fibrosis dominance into gene-editing treatments for blood disorders and pain management, targeting $13.1B revenue with non-CF products generating $500M+.
VRTXbiotechpharmaceutical innovation